Cargando…

Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised

The concentration of nanoparticles in the ambient air can lead to induced toxicities; however, it appears that nanoparticles’ unique properties are completely omitted when assessing health risks. This paper aims to enhance the EPA health risk assessment by incorporating two new variables that consid...

Descripción completa

Detalles Bibliográficos
Autores principales: Macko, Michal, Antoš, Jan, Božek, František, Konečný, Jiří, Huzlík, Jiří, Hegrová, Jitka, Kuřitka, Ivo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823543/
https://www.ncbi.nlm.nih.gov/pubmed/36615930
http://dx.doi.org/10.3390/nano13010020
_version_ 1784866185566748672
author Macko, Michal
Antoš, Jan
Božek, František
Konečný, Jiří
Huzlík, Jiří
Hegrová, Jitka
Kuřitka, Ivo
author_facet Macko, Michal
Antoš, Jan
Božek, František
Konečný, Jiří
Huzlík, Jiří
Hegrová, Jitka
Kuřitka, Ivo
author_sort Macko, Michal
collection PubMed
description The concentration of nanoparticles in the ambient air can lead to induced toxicities; however, it appears that nanoparticles’ unique properties are completely omitted when assessing health risks. This paper aims to enhance the EPA health risk assessment by incorporating two new variables that consider the size of nanoparticles: the toxicity multiplier and the size multiplier. The former considers the qualitative aspect of the size of particles within a concentration, whilst the latter takes into account the effects associated with the number of particles of the specific i-th size distribution interval. To observe the impact of the new variables, a case study was performed. The studied element was cadmium, which was measured using ICP-MS to discover concentrations of size fractions, ranging from <15.1 to <9830 nm. Next, the cadmium concentration is assessed using both the current state-of-the-art method and the proposed method with adjustments. Based on the new approach, the final risk was 1.1 × 10(−5), which was almost 24 times higher compared with the current method. The contribution of nanoparticles to the risk value grew from barely 6% to an alarming 88%. Therefore, the enhanced method can lead to more realistic results when assessing the health risks of nanoparticles.
format Online
Article
Text
id pubmed-9823543
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98235432023-01-08 Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised Macko, Michal Antoš, Jan Božek, František Konečný, Jiří Huzlík, Jiří Hegrová, Jitka Kuřitka, Ivo Nanomaterials (Basel) Article The concentration of nanoparticles in the ambient air can lead to induced toxicities; however, it appears that nanoparticles’ unique properties are completely omitted when assessing health risks. This paper aims to enhance the EPA health risk assessment by incorporating two new variables that consider the size of nanoparticles: the toxicity multiplier and the size multiplier. The former considers the qualitative aspect of the size of particles within a concentration, whilst the latter takes into account the effects associated with the number of particles of the specific i-th size distribution interval. To observe the impact of the new variables, a case study was performed. The studied element was cadmium, which was measured using ICP-MS to discover concentrations of size fractions, ranging from <15.1 to <9830 nm. Next, the cadmium concentration is assessed using both the current state-of-the-art method and the proposed method with adjustments. Based on the new approach, the final risk was 1.1 × 10(−5), which was almost 24 times higher compared with the current method. The contribution of nanoparticles to the risk value grew from barely 6% to an alarming 88%. Therefore, the enhanced method can lead to more realistic results when assessing the health risks of nanoparticles. MDPI 2022-12-21 /pmc/articles/PMC9823543/ /pubmed/36615930 http://dx.doi.org/10.3390/nano13010020 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Macko, Michal
Antoš, Jan
Božek, František
Konečný, Jiří
Huzlík, Jiří
Hegrová, Jitka
Kuřitka, Ivo
Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised
title Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised
title_full Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised
title_fullStr Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised
title_full_unstemmed Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised
title_short Development of New Health Risk Assessment of Nanoparticles: EPA Health Risk Assessment Revised
title_sort development of new health risk assessment of nanoparticles: epa health risk assessment revised
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823543/
https://www.ncbi.nlm.nih.gov/pubmed/36615930
http://dx.doi.org/10.3390/nano13010020
work_keys_str_mv AT mackomichal developmentofnewhealthriskassessmentofnanoparticlesepahealthriskassessmentrevised
AT antosjan developmentofnewhealthriskassessmentofnanoparticlesepahealthriskassessmentrevised
AT bozekfrantisek developmentofnewhealthriskassessmentofnanoparticlesepahealthriskassessmentrevised
AT konecnyjiri developmentofnewhealthriskassessmentofnanoparticlesepahealthriskassessmentrevised
AT huzlikjiri developmentofnewhealthriskassessmentofnanoparticlesepahealthriskassessmentrevised
AT hegrovajitka developmentofnewhealthriskassessmentofnanoparticlesepahealthriskassessmentrevised
AT kuritkaivo developmentofnewhealthriskassessmentofnanoparticlesepahealthriskassessmentrevised